In molecular biology, biochemistry and cell signaling the kinome of an organism is the complete set of protein kinases encoded in its genome. Kinases are usually enzymes that catalyze phosphorylation reactions (of amino acids) and fall into several groups and families, e.g., those that phosphorylate the amino acids serine and threonine, those that phosphorylate tyrosine and some that can phosphorylate both, such as the MAP2K and GSK families. The term was first used in 2002 by Gerard Manning and colleagues in twin papers analyzing the 518 human protein kinases, and refers to both protein kinases and protein pseudokinases and their evolution of protein kinases throughout the eukaryotes. Other kinomes have been determined for rice, several fungi, nematodes, and insects, sea urchins, Dictyostelium discoideum, and the process of infection by Mycobacterium tuberculosis. Although the primary sequence of protein kinases shows substantial divergence between unrelated eukaryotes, and amino acid differences in catalytic motifs have permitted their separation of kinomes into canonical and pseudokinase subtypes, the variation found in the amino acid motifs adjacent to the site of actual phosphorylation of substrates by eukaryotic kinases is much smaller.
Videojet Technologies Ltd.
http://www.videojet.co.uk
|
Videojet Technologies Ltd., part of Danaher Corp., is a British company located in Huntingdon. The firm sells and distributes printers and laser marking machines.\nThe company says this about itself: Videojet Technologies is a world-leader in the product identification market, providing in-line printing, coding, and marking products, application specific fluids, and product LifeCycle AdvantageTM.
Power transmission
Electronics
Laser
Product identification
Application specific
Maanshan Weitai Biotechnology Co., Ltd.
Maanshan Weitai Biotechnology Co., Ltd., established on 2018-12-05, Business scope includes biotechnology extension services;Production and sales of health products,food additives,Pharmaceutical Intermediates,Biological Nucleotides,Biological enzyme preparations and key components and related intermediates,Chemical Reagents and Auxiliaries,Non-medical biological substances and reagents(The above production and sales items except dangerous chemicals and precursor drugs);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate and prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)
Hangzhou Weitai Biological Pharmaceutical Co., Ltd.
http://www.biologicalenzyme.com
|
Hangzhou Weitai Biological Pharmaceutical Co., Ltd., established on 2019-05-22, Business scope includes biotechnology extension services;production and sales:food additives,Pharmaceutical Intermediates,Biological Nucleotides,biological enzyme preparation,Chemical Reagents and Auxiliaries,biological reagent(The above production and sales items except dangerous chemicals and precursor drugs);Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)
Bharat Biotech International Ltd.
http://www.bharatbiotech.com
|
Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India..
Chikungunya
Medicine
Conjugate vaccine
Toxoid
DNA vaccination
Clinical trial
Gastrointestinal agent
Infection drug
Cancer vaccine
Drug development
Drug discovery
Pneumococcal vaccine
Soil treatment
Biotechnology
Ebola vaccine
Pneumococcal conjugate vaccine
Orphan drug
HIV vaccine
Pesticide
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,
Oncology
Medicine
Drug
Oncology drugs
Colorectal cancer
Drug development
Biotechnology
Drug discovery
Bone metastasis
Tocilizumab
Biomedicine
Rituximab
Biopharmaceutical
Clinical trial
Microbiome
Enzyme
Cancer immunotherapy
Gastrointestinal agent
Immunotherapy
Trustees of Dartmouth College
http://www.dartmouth.edu
|
Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline.
The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche.
Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.
Biotechnology
Biology
Medicine
Bevacizumab
Oncology drugs
Monoclonal antibody
Drug discovery
Rituximab
Immunotherapy
Biopharmaceutical
Cancer immunotherapy
Cisplatin
Paclitaxel
Pharmaceutical manufacturing
Genomics
Carboplatin
Cardiovascular agent
Biomedicine
Tocilizumab
Ixabepilone
AEterna Zentaris GmbH engages in biopharmaceutical research. It specializes in the fields of oncology and endocrinology. The company is headquartered in Frankfurt, Germany.
Oncology
Endocrinology
Medicine
Biotechnology
Biomedicine
Biopharmaceutical
Oncology drugs
Exosome
Biophysics
Cell signaling
Biochemistry
Bone metastasis
Antidiuretic
Lung cancer
Cancer vaccine
Adenomyosis
Amenorrhea
Vaginitis
Prostate cancer
The General Hospital Corp.
http://www.massgeneral.org
|
Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve.
They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.
Vascular Medicine
Digestive disorder
Subspecialty
Heart disease
Surgery
BioBlocks, Inc.
http://www.bioblocks.com
|
BioBlocks, Inc., part of Genesis Biotechnology Group LLC, is an American company located in San Diego, CA, that provides medicinal chemistry drug discovery services and products to clients. It was founded in 2002 by Peter Pallai, he has been the CEO since the inception date. On October 07, 2021 Genesis Drug Discovery & Development LLC acquired BioBlocks, Inc.\nThe company says this about itself: BioBlocks is a collaborative medicinal chemistry research organization that focuses on drug discovery from initial hit through identification of development candidates. We provide expertise and join forces with our clients to discover compounds qualified for advancement to phase two clinical trials. Aided by a results-based lead optimization model, BioBlocks scientists have developed multiple preclinical candidates for its partners. The Company's Leap-to-Lead platform provides an alternative source for high-quality tractable leads with multiple possible optimization pathways.
Medicinal chemistry
Drug discovery
Lead compound
Lab-on-a-chip
High-throughput screening
Bioavailability
Clinical trial
Contract research organization
Microfluidics
Biomedicine
Biotechnology
China Ocean Mineral Resources R&D Association
The Institute for Cancer Research
Emiliem, Inc is a private biotechnology company focused on understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions. The company is particularly interested in diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.
Biotechnology
Adverse drug reaction
Determinant
Rare disease
Drug
Cell Signaling Technology, Inc.
http://www.cellsignal.com
|
Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.
Cell signaling
Medical equipment
Cell
Antibody
Immunohistochemistry
Cell signaling pathways
Biotechnology
Cancer research
Reagent
Histology
Flow cytometry
Pathology
Contract research organization
Immunofluorescence
Monoclonal antibody
Stem cell culture
Induced pluripotent stem cell
Microarray
Stem cell
Metabolomics
Lexicon Pharmaceuticals, Inc.
http://www.lexpharma.com
|
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.
Clinical trial
Medicine
Drug discovery
Drug development
Ophthalmology
Cardiology
Carcinoid syndrome
Tocilizumab
Type 2 diabetes
Biomedicine
Immunotherapy
Rituximab
Biotechnology
Monoclonal antibody
Biopharmaceutical
Irritable bowel syndrome
Insulin
Rheumatoid arthritis
Glaucoma
Visionary Pharmaceuticals, Inc.
http://www.visionarypharmaceutical.com
|
Visionary Pharmaceuticals is a leading biotechnology company developing first-in-class drugs for unmet medical needs in Cancer and Inflammation.
The founders of Visionary Pharmaceuticals have more than 60 years of combined experience in drug discovery and have importantly contributed to multiple drugs that are on the market or in late-stage clinical trials. The company has deep expertise in translating new chemical entities to the clinic and is poised to deliver innovative nuclear receptor modulators to treat Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, COPD and Cancer.
Medicine
Drug
Inflammation
Biotechnology
Nuclear receptor
New chemical entity
COPD
Rheumatoid arthritis
Multiple sclerosis
Drug discovery
Clinical trial
Beijing Prime Gene Therapeutics Co., Ltd.
https://www.primegene.net/
|
Beijing Prime Gene Therapeutics Co., Ltd. is an innovative pharmaceutical company based in China and facing the world. Based on filling unmet clinical needs, the company focuses on new drug discovery, R&D and commercialization featuring immune/inflammatory diseases and external use, and is committed to becoming a leading international pharmaceutical company.
Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
http://www.lynkpharma.com
|
Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China) is a company headquartered in Hangzhou, China, with subsidiaries in Hong Kong. The firm engages in research and development of small-molecule drugs for tumors and autoimmune diseases. It was founded in 2017 by Michael Vazquez, Zhao Kui Wan, Yan Chen and Jun Wang. Zhao Kui Wan is the CEO, in this role since 2018.\nThe company says this about itself: Lynk Pharmaceuticals, a clinical stage company, was founded in 2018 by senior drug R&D experts and executives from Pfizer, Merck, and Johnson & Johnson. Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of cancer, as well as immune and inflammatory diseases. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader to address unmet medical demands by the development of innovative therapies. To date, Lynk Pharmaceuticals has independently developed a number of innovative new drugs, and independently as well as jointly with its US partner launched a number of clinical studies globally.
People also interested in
Rare diseaseTocilizumabAntidiureticPathologyOphthalmologyBiophysicsCardiologyBiomedicineInsulinClinical trial